ArticleClinical and translational medicine2025

SHP2 inhibition and adjuvant therapy synergistically target KIT-mutant GISTs via ERK1/2-regulated GSK3β/cyclin D1 pathway.

Chunxiao He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.